More importantly, our data indicate that administration of the PPARβ/δ antagonist led to a condition resembling left ventricular hypertrophy (LVH) in obesity, characterized by an abnormal increase in left ventricular myocardial volume while still maintaining a preserved ejection fraction. Here, PPARD is linked to Obesity.